Publications
You can download this List with "Publications and
Abstarct" as 
| P1 | Burckhardt JJ, Guggisberg E, Fellenberg R von. Thymus immunoglobulin receptors. Ontogenic development, response to antigenic stimulation, and their possible role in the regulation of "aggressive" immune reactions. Immunology 26, 521-538, 1974. |
| P2 | Guggenheim B, Burckhardt JJ. Isolation and properties of a dextranase from Streptococcus mutans OMZ 176. Helv. odontol. Acta 18, 101-113, 1974. |
| P3 | Burckhardt JJ, Guggenheim B. Interactions of antisera, sera, and oral fluid with glucosyltransferase. Infect, Immunity 13, 1009-1022, 1976. |
| P4 | Burckhardt JJ, Guggenheim B, Hefti A. Are Actinomyces viscosus antigens B-cell mitogens? J. Immunol. 118, 1460-1465, 1977. |
| P5 | Guggenheim B, Hefti A, Burckhardt JJ. The effect of cyclosporin A on dental caries in rats monoassociated with Actinomyces viscosUS Ny 1. In. Secretory Immunity and Infection. McGhee JR, Mestecky J, Babb JL (Eds.). Advances in Experimental Medicine and Biology, Vol. 107, Plenum Press, New York, 1978, pp. 293-301. |
| P6 | Burckhardt JJ. Rat memory T lymphocytes. in vitro proliferation induced by antigens of Actinomyces viscosus. Scand. J. Immunol. 7, 167-172, 1978. |
| P7 | Burckhardt JJ, Guggenheim B. Cyclosporin A. in vivo and in vitro suppression of rat lymphocyte function. Immunology 36, 753-757, 1979. |
| P8 | Burckhardt JJ. Rat memory T lymphocytes. Il. Differences in macrophage-dependent activation shown by Actinomyces viscosus antigens and by mitogens using silica in vitro. Scand. J. Immunol. 10, 229-235, 1979. |
| P9 | Burckhardt JJ, Guggenheim B. Increased smooth-surface caries incidence in gnotobiotic rats immunized with Actinomyces viscosus. Caries Res. 14, 56-59, 1980. |
| P10 | Marchalonis JJ, Warr GVV, Santucci LA, Szenberg A, Fellenberg R von, Burckhardt JJ. The immunoglobulin-like T cell receptor. IV. Quantitative cellular assay and partial characterization of a hcavy chain crossreactive with Fdp. Mol. Immunol. 17, 985-999, 1980. |
| P11 | Guggenheim B, Gaegauf-Zollinger R, Hefti A, Burckhardt JJ. The effect of cyclosporin A on periodontal disease in rats monoassociated with Actinomyces viscosus
Nyl. J. Periodont. Res. 16, 26-38, 1981. |
| P12 | Burckhardt JJ; Gaegauf-Zollinger R, Guggenheim B. Development of immunological sensitization and alveolar bone loss in gnotobiotic rats infected with Actinomyces viscosus
Nyl. J. Periodont. Res. 16, 147-158, 1981. |
| P13 | Burckhardt JJ, Gaegauf-Zollinger R, Schmid R, Guggenheim B. Alveolar bone loss in rats after immunization with Actinomyces viscosus. Infect. Imrnunity 31, 971-977, 1981. |
| P14 | Gaegauf-Zollinger R, Burckhardt JJ, Guggenheim B. Radiographic measurement of alveolar bone loss in the rat. Archs. Oral Biol. 27, 651-658, 1982. |
| P15 | Gaegauf-Zollinger R, Burckhardt JJ, Gmür R, Guggenheim B. Cell-mediated cytotoxicity against rat fibroblasts induced by Actinomyces viscosus. Infect. Immunity ~7, 710-719, 1982. |
| P16 | Burckhardt JJ, Anderson WHK, Kearney J., Cooper MD, A distinct cell surface component of human blood monocytes identified by a monoclonal antibody. Blood 60, 767-7715 1982. |
| P17 | Burckhardt JJ. Lymphocyte interactions in host responses to oral infections caused by Actinomyces viscosus. In. Biological, Biochemical, and Biomedical Aspects of Actinomycetes. Ortiz-Ortiz, L., Bojalil LF, Yakoleff V (Eds.) Academic Press, Inc., Orlando, 1984, pp. 47-60. |
| P18 | Burckhardt JJ, Born P, Pletscher VV. Antibody determination in an ongoing hepatitis B vaccination program. J. Med. Virol. 20, 199-206, 1986. |
| P19 | Brodbeck H, Born P, Weisskopf H, Baumann E, Ryff J-Ch, Burckhardt JJ. Evaluation of the new HBeAg EIA and Anti-HBe EIA by monitoring patients with chronic active hepatitis B receiving recombinant interferon alfa-2a. In. Viral Hepatitis and Liver Disease. Zuckerman AJ (Ed.) A.R. Liss, Inc., New York, 1988, pp. 252-257. |
| P20 | Blaser K, Burckhardt JJ, Carrel S, Heusser Ch, Nydegger U, Riesen VV. Therapeutic possibilities with monoclonal antibodies (in german). Part 1. Fundamental aspects. Labor - Medizin 12, 191-202, 1989. Part 2. Therapy of malignant tumours by monoclonal antibodies. Labor - Medizin 12, 275-281, 1989. Part 3. Production, safety and efficacy of monoclonal antibodies. Labor - Medizin 12, 328-341, 1989. |
| P21 | Burckhardt JJ, Gardi A, Oxelius VA, Preud'homme JL, Scherz R, Skvaril F, Heiniger HJ. Immunoglobulin G subciass distribution in three human intravenous immunoglobulin preparations. Vox Sanguinis 57, 10-14, 1989. |
| P22 | Gerber H, Spâth PJ, Perret BA, Burckhardt JJ. Laboratory workshop on the characterization of antiplatelet antibodies in immune thrombocytopenic purpura. Blut 59, 61-66, 1989. |
| P23 | Spycher MO, Hoffrnan R, Spâth PJ, Burckhardt JJ, Fearon DT. Measurement by flow cytometry of intracellular free Ca++ concentration and complement receptor expression in activated neutrophils and monocytes. Protides of the Biological Fluids 36, 277-285, 1989. |
| P24 | Burckhardt JJ, Bütler-Brunner E, Perrin LH, Bachmann P In. Autologous transfusion practice, controversies about current fashions and real needs. Zuck TF, Carey PM (Eds. International Forum). Vox Sanguinis 58, 234-253, 1990, pp 242-245. |
| P25 | Perrin LH, Yerly S, Adami N, Bachmann P, Bütler-Brunner E, Burckhardt J, Kawashima E. Human immunodeficiency virus DNA amplification and serology in blood donors. Blood 76, 641-645, 1990. |
| P26 | Burckhardt JJ, Friedli H, Gardi A, Heiniger HJ. Alanine aminotransferase screening and hepatitis C virus antibody. Lancet 336, 447-448, 1990. |
| P27 | Burckhardt JJ. Was bedeutet ein positiver Antikôrperbefund gegen das Hepatitis-C-Virus (anti-HCV) bei Blutspendern? Bulletin Bundesamt für Gesundheitswesen 1990;45:738-740. |
| P28 | Spycher MO, Spycher-Burger M, Spâth PJ, Burckhardt JJ. Human serum induced opsonization of immunoglobulin G coated polystyrene microspheres with complement components C3 and C4 as measured by flow cytometry. J.Immunol.Methods 145, 83-92, 1991. |
| P29 | Perret BA, Morell A, Burckhardt JJ. Keine HCV-Serokonversion nach Substitution von Hâmophilen mit Viren-inaktivierten Gerinnungsfaktor Vlll- und IX-Konzentraten. Schweiz. med. Wschr. 121, (44)1621-1623, 1991. |
| P30 | Burckhardt JJ. Übertragung von Infektionskrankheiten durch Blutprâparate in der Schweiz; Fortschritte in der Virusinaktivierung. Schweiz. Z. Milit. Med. 68, (3).61-65, 1991. |
| P31 | Burckhardt JJ, Bachmann P. Seroprâvalenz von Infektionserregern in der Schweiz. wie gross ist das Restrisiko? Klinisches Laboratorium, 38. 380-384, 1992. |
| P32 | Perret BA, Senn M, Poorbeik M, Burckhardt JJ, Morell A. Hepatitis-C-Virus-Serostatus der Hamophilen in der Schweiz. Schweiz. med. Wschr. 123. 79-81, 1993. Johann J. Burckhardt List of Publications and Abstracts 2002-11-19 3/9 |
| P33 | Burckhardt JJ. Sicherheit von Blutprâparaten heute. Spenderselektion und Virusinaktivierung. In Moderne Chirurgie und Blutersatz. Ammann J, Morell A (Eds.) Reihe "Aktuelle Probleme in Chirurgie und Orthopâdie", Hans Huber, Bern. 1995. |
| P34 | Burckhardt JJ, Bachmann P, Perrin LH. Performances et limites des tests de dépistage des maladies transmissibles dans le cadre de la transfusion sanguine. Méd et Hyg 1994;52:1006-1013. |
| P35 | Torresani T, Grüters A, Scherz R, Burckhardt JJ, Harras A, Zachmann M. Improving the efficacy of newborn screening for congenital adrenal hyperplasia by adjusting the cut-off level of 17OEhydroxyprogesterone to gestational age. Screening 1994;3:77-84. |
| P36 | von Graevenitz A, Pfyffer GE, Burckhardt JJ. The Swiss external quality control systern in microbiology. Med Microbiol Lett 1995;4:31-34. |
| P37 | Blumberg A, Zehnder C, Burckhardt JJ. Prevention of hepatitis C infection in haemodialysis units. A prospective study. Nephrol Dial Transplant 1995-110:230-233. |
| P38 | Bachmann P, Oberli M, Burckhardt JJ. The Swiss Blood Testing Unit, an innovative project to prevent transfusion-transmitted diseases. Laboratory Robotics and Automation 1997;9:249-253. |
| P39 | Kasulke D, Dengler T, Bachmann P, Rudolf A, Burckhardt JJ. Evaluation of a testing laboratory in a transportable housing unit for screening of blood donation samples. Clînical Laboratory 1998,44:373-378. |
| P40 | Böni J, Pyra H, Gebhardt M, Perrin L, Bürgisser P, Matter L, Fierz W, Erb P, Piffaretti J-C, Minder E, Grob P, Burckhardt JJ, Zwahlen M, Schüpbach J. High frequency of non-B subtypes in newly diagnosed HIV-1 infections in Switzerland. AIDS 1999122:174-179. |
| P41 | Burckhardt JJ. Assessment of needs for plasma for fractionation in Europe. Biologicals 1999; 27(4):337-41. |
| P42 | Schüpbach J, Burckhardt JJ, Grob P, Bürgisser Ph, Perrin LH, Gorgievski M, Erb P,Fierz W, Piffaretti JC. Prävalenz von Infektionen mit dem humanen T-Zell Leukämievirus 1 oder 2 in der Schweiz. Bulletin Bundesamt für Gesundheit 2002;07:116-120. |
| P43 | Böni J, Bisset LR, Burckhardt JJ,Joller HI, Bürgisser P, Perrin L, Gorgievski M, Erb P, Fierz W, Piffaretti JC, Schüpbach J and the Swiss HIV Cohort Study. Prevalence of Human T-cell Leukemia Virus (HTLV) types I and II in Switzerland. J Med Virology, accepted July 2003. |
| PATENT | Burckhardt JJ, Staehelin T, Stocker J. Markiertes, immunologisch aktives Mittel, dessen Herstellung
und dessen Verwendung in einern immunologischen Nachweis- oder Bestimmungsverfahren. Anmeldung Nr. 82107048.9, 04.08.1982. F. Hoffmann-La Roche, Co. Aktiengesellschaft. |
